---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-029968"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:55:24.136224+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics presents Phase 1b data showing stable MDS-UPDRS and biomarker improvements for GT-02287 at AD/PD 2026

## Summary
- Phase 1b: 19 completed Part 1, 16 entered extension; DMC approved continuation without changes.
- MDS-UPDRS scores stable over 150 days; high GluSph group showed 6.7-point difference vs low group.
- DDC decreased after 90 days in high GluSph baseline group, supporting disease-modifying potential.
- Preclinical data for novel GCase modulator GT-04686 presented, ready for IND-enabling studies.
- Extension study expected to complete September 2026.

## SEC filing metadata
- accession: 0001104659-26-029968
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465926029968/0001104659-26-029968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465926029968/tm269191d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-029968
- JSON: https://secwatch.observer/filing/0001104659-26-029968.json
- Plain text: https://secwatch.observer/filing/0001104659-26-029968.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.